Departamento de Neurologia e Neurocirurgia, Universidade Federal de São Paulo, Av. Moema 170, Cj. 83. Moema, São Paulo, SP, 04077-020, Brazil.
Serviço de Terapia Intensiva, Hospital Santa Paula, São Paulo, Brazil.
Neurocrit Care. 2021 Apr;34(2):581-592. doi: 10.1007/s12028-020-01052-9. Epub 2020 Jul 17.
The efficacy objective was to determine whether a novel nasopharyngeal catheter could be used to cool the human brain after traumatic brain injury, and the safety objective was to assess the local and systemic effects of this therapeutic strategy.
This was a prospective, non-randomized, interventional clinical trial that involved five patients with severe traumatic brain injury. The intervention consisted of inducing and maintaining selective brain cooling for 24 h by positioning a catheter in the nasopharynx and circulating cold water inside the catheter in a closed-loop arrangement. Core temperature was maintained at ≥ 35 °C using counter-warming.
In all study participants, a brain temperature reduction of ≥ 2 °C was achieved. The mean brain temperature reduction from baseline was 2.5 ± 0.9 °C (P = .04, 95% confidence interval). The mean systemic temperature was 37.3 ± 1.1 °C at baseline and 36.0 ± 0.8 °C during the intervention. The mean difference between the brain temperature and the systemic temperature during intervention was - 1.2 ± 0.8 °C (P = .04). The intervention was well tolerated with no significant changes observed in the hemodynamic parameters. No relevant variations in intracranial pressure and transcranial Doppler were observed. The laboratory results underwent no major changes, aside from the K levels and blood counts. The K levels significantly varied (P = .04); however, the variation was within the normal range. Only one patient experienced an event of mild localized and superficial nasal discoloration, which was re-evaluated on the seventh day and indicated complete recovery.
The results suggest that our noninvasive method for selective brain cooling, using a novel nasopharyngeal catheter, was effective and safe for use in humans.
本研究旨在评估一种新型鼻咽导管用于颅脑创伤后脑降温的有效性,以及评估该治疗策略的局部和全身安全性。
这是一项前瞻性、非随机、干预性临床试验,共纳入 5 例重型颅脑创伤患者。干预措施包括通过将导管置于鼻咽部并用闭路循环在导管内循环冷水来诱导和维持 24 小时的选择性脑冷却。通过反调节将核心温度维持在≥35℃。
所有研究参与者的脑温均降低≥2℃。与基线相比,脑温平均降低 2.5±0.9℃(P=0.04,95%置信区间)。基线时平均全身温度为 37.3±1.1℃,干预期间为 36.0±0.8℃。干预期间脑温与全身温度的平均差值为-1.2±0.8℃(P=0.04)。该干预措施耐受性良好,血流动力学参数无明显变化。未观察到颅内压和经颅多普勒有相关变化。实验室结果除 K 水平和血细胞计数外,无明显变化。K 水平明显变化(P=0.04);然而,变化在正常范围内。只有 1 例患者出现轻度局部和浅表性鼻变色,第 7 天再次评估时表明已完全恢复。
我们的研究结果表明,使用新型鼻咽导管进行非侵入性选择性脑冷却的方法对人体有效且安全。